JP2023535024A5 - - Google Patents

Info

Publication number
JP2023535024A5
JP2023535024A5 JP2023504285A JP2023504285A JP2023535024A5 JP 2023535024 A5 JP2023535024 A5 JP 2023535024A5 JP 2023504285 A JP2023504285 A JP 2023504285A JP 2023504285 A JP2023504285 A JP 2023504285A JP 2023535024 A5 JP2023535024 A5 JP 2023535024A5
Authority
JP
Japan
Prior art keywords
sequence
antibody
seq
heavy chain
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023504285A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023535024A (ja
JP7895922B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/042900 external-priority patent/WO2022020680A1/en
Publication of JP2023535024A publication Critical patent/JP2023535024A/ja
Publication of JP2023535024A5 publication Critical patent/JP2023535024A5/ja
Application granted granted Critical
Publication of JP7895922B2 publication Critical patent/JP7895922B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023504285A 2020-07-23 2021-07-23 抗aベータ抗体 Active JP7895922B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063055813P 2020-07-23 2020-07-23
US63/055,813 2020-07-23
US202063086589P 2020-10-01 2020-10-01
US63/086,589 2020-10-01
US202163187379P 2021-05-11 2021-05-11
US63/187,379 2021-05-11
US202163219611P 2021-07-08 2021-07-08
US63/219,611 2021-07-08
PCT/US2021/042900 WO2022020680A1 (en) 2020-07-23 2021-07-23 Anti-abeta antibodies

Publications (3)

Publication Number Publication Date
JP2023535024A JP2023535024A (ja) 2023-08-15
JP2023535024A5 true JP2023535024A5 (cg-RX-API-DMAC7.html) 2024-10-15
JP7895922B2 JP7895922B2 (ja) 2026-07-28

Family

ID=79728984

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023504285A Active JP7895922B2 (ja) 2020-07-23 2021-07-23 抗aベータ抗体

Country Status (16)

Country Link
US (9) US12435129B2 (cg-RX-API-DMAC7.html)
EP (1) EP4185612A4 (cg-RX-API-DMAC7.html)
JP (1) JP7895922B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230039734A (cg-RX-API-DMAC7.html)
CN (1) CN116348487A (cg-RX-API-DMAC7.html)
AU (1) AU2021310926A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023001061A2 (cg-RX-API-DMAC7.html)
CA (1) CA3186614A1 (cg-RX-API-DMAC7.html)
CL (3) CL2023000216A1 (cg-RX-API-DMAC7.html)
IL (1) IL300059A (cg-RX-API-DMAC7.html)
JO (1) JOP20230017A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023000949A (cg-RX-API-DMAC7.html)
PH (1) PH12023550178A1 (cg-RX-API-DMAC7.html)
PY (1) PY2160662A (cg-RX-API-DMAC7.html)
UY (1) UY39337A (cg-RX-API-DMAC7.html)
WO (1) WO2022020680A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021310926A1 (en) 2020-07-23 2023-03-23 Othair Prothena Limited Anti-abeta antibodies
CN120513256B (zh) * 2023-01-20 2026-07-10 迈威(美国)生物治疗有限公司 抗淀粉样蛋白β原纤丝/低聚物抗体和其用途
TW202434629A (zh) * 2023-01-26 2024-09-01 愛爾蘭商歐薩爾普羅席納有限公司 以抗類澱粉β (ABETA)抗體治療神經病症之方法
KR20260049797A (ko) * 2023-07-12 2026-04-14 로이드 트란 경도 인지 장애 치료를 위한 병용 요법의 치료제 조성물 및 사용 방법
AU2025206067A1 (en) * 2024-01-05 2026-07-23 Othair Prothena Limited Methods of treating neurological disorders with anti-abeta antibodies
WO2026122407A1 (en) * 2024-12-04 2026-06-11 Merck Sharp & Dohme Llc Amyloid beta binder, and uses thereof

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3003097A (en) 1958-07-17 1961-10-03 Gen Electric Sequence control system for timing motor
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6518011B1 (en) 1999-01-13 2003-02-11 Bristol-Myers Squibb Company Method for screening compounds to identify beta-amyloid production modulators
MY128897A (en) 1999-02-05 2007-02-28 Samsung Electronics Co Ltd Image texture retrieving method and apparatus thereof
US7629311B2 (en) 1999-02-24 2009-12-08 Edward Lewis Tobinick Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
EA006606B1 (ru) 2000-02-24 2006-02-24 Вашингтон Юниверсити Гуманизированное антитело и его фрагмент, взаимодействующие с бета-амилоидным пептидом, и способы их применения
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
AU2002258808A1 (en) 2001-04-30 2002-11-11 Eli Lilly And Company Humanized antibodies
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
WO2004029629A1 (en) 2002-09-27 2004-04-08 Janssen Pharmaceutica N.V. N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses
CA2520853A1 (en) 2003-03-28 2005-03-31 Centocor, Inc. Anti-amyloid antibodies, compositions, methods and uses
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
WO2005012877A2 (en) 2003-08-01 2005-02-10 Dna Twopointo Inc. Systems and methods for antibody engineering
US8005620B2 (en) 2003-08-01 2011-08-23 Dna Twopointo Inc. Systems and methods for biopolymer engineering
WO2005018424A2 (en) 2003-08-18 2005-03-03 Research Foundation For Mental Hygiene, Inc. Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
AU2005290250A1 (en) 2004-07-30 2006-04-06 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
EA200700751A1 (ru) 2004-10-05 2008-06-30 Элан Фарма Интернэшнл Лимитед Способы и композиции для улучшения продуцирования рекомбинантного белка
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
US20060257396A1 (en) 2004-12-15 2006-11-16 Jacobsen Jack S Abeta antibodies for use in improving cognition
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
BRPI0611600B8 (pt) 2005-06-17 2021-05-25 Wyeth Corp método para purificação de uma proteína tendo uma região fc a partir de um líquido fonte compreendendo a proteína e uma ou mais impurezas, e kit
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
CA2632828C (en) 2005-12-12 2012-07-10 F. Hoffmann-La Roche Ag Antibodies against amyloid beta with glycosylation in the variable region
KR101263294B1 (ko) 2006-03-30 2013-06-04 글락소 그룹 리미티드 아밀로이드­베타 펩티드에 대한 항체
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
RU2498999C2 (ru) 2006-07-14 2013-11-20 Ац Иммуне Са Гуманизированное антитело к амилоиду бета
WO2008030251A1 (en) 2006-09-08 2008-03-13 Georgetown University Deglycosylated anti-amyloid beta antibodies
HUE033466T2 (en) 2006-10-02 2017-12-28 Ac Immune Sa Humanized antibody to beta-amyloid
HUE033325T2 (en) 2007-01-05 2017-11-28 Univ Zuerich Anti-beta-amyloid binder antibodies and their use
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
WO2008131298A2 (en) 2007-04-18 2008-10-30 Elan Pharma International Limited Prevention and treatment of cerebral amyloid angiopathy
HRP20150086T1 (xx) 2007-06-12 2015-02-27 Ac Immune S.A. Humanizirana antitijela za beta amiloid
ES2498040T3 (es) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
AU2008311366B2 (en) 2007-10-05 2015-03-12 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US20100291071A1 (en) 2008-08-01 2010-11-18 Immunas Pharma, Inc. Antibody Specific Binding to A-Beta Oligomer and the Use
KR20100115340A (ko) 2007-10-19 2010-10-27 이무나스 파마 가부시키가이샤 Aβ 올리고머에 특이적으로 결합하는 항체 및 그의 이용
AU2008322523B2 (en) 2007-11-16 2013-10-10 The Rockefeller University Antibodies specific for the protofibril form of beta-amyloid protein
PL2246427T3 (pl) 2008-02-08 2017-06-30 Immunas Pharma, Inc. Przeciwciała zdolne do wiązania się swoiście do oligomerów amyloidu beta i ich stosowanie
KR20110016959A (ko) 2008-06-03 2011-02-18 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
US7561973B1 (en) 2008-07-31 2009-07-14 Dna Twopointo, Inc. Methods for determining properties that affect an expression property value of polynucleotides in an expression system
US8126653B2 (en) 2008-07-31 2012-02-28 Dna Twopointo, Inc. Synthetic nucleic acids for expression of encoded proteins
US8822645B2 (en) 2008-07-08 2014-09-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
WO2010004434A2 (en) 2008-07-09 2010-01-14 University Of Zurich Method of promoting neurogenesis
WO2010030203A1 (en) 2008-09-09 2010-03-18 Biocodex - Incubação De Empresas De Ciências Da Vida, S.A. Monoclonal antibody to human amyloidogenic and modified forms of transthyretin and its use in the detection and treatment of fap and pathologies presenting modified ttr
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
JP5812418B2 (ja) 2009-04-17 2015-11-11 イムナス・ファーマ株式会社 Aβオリゴマーに特異的に結合する抗体およびその利用
US8512677B2 (en) 2009-04-27 2013-08-20 Case Western Reserve University Pyro-glutamate Aβ targeting agents
BRPI1012195A2 (en) 2009-05-01 2018-04-24 Abbott Laboratories double variable domain immunoglobulins and their uses
WO2011000095A1 (en) 2009-07-02 2011-01-06 Angiochem Inc. Multimeric peptide conjugates and uses thereof
WO2011016238A1 (en) 2009-08-06 2011-02-10 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
WO2011031720A1 (en) 2009-09-11 2011-03-17 Arizona Board Of Regents Acting For And On Behalf Of Arizona State University Bispecific nanobodies as a therapeutic for alzheimer's disease
PH12012501744A1 (en) 2010-03-03 2021-08-09 Boehringer Ingelheim Int Biparatopic abeta binding polypeptides
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
US9320793B2 (en) 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
SI3339323T1 (sl) 2010-08-12 2019-12-31 Eli Lilly And Company Protitelesa proti N3PGLU amiloid beta peptidu in njihove uporabe
WO2012021475A2 (en) 2010-08-12 2012-02-16 Eli Lilly And Company ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
WO2012136552A1 (en) 2011-04-08 2012-10-11 H. Lundbeck A/S ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ
US9534016B2 (en) 2011-11-28 2017-01-03 Buck Institute For Research On Aging Netrin loop peptide mimetics and uses thereof
EP2807188B1 (en) * 2012-01-27 2019-09-11 Prothena Biosciences Limited Humanized antibodies that recognize alpha-synuclein
ITRM20120383A1 (it) 2012-03-20 2013-09-21 Uni Degli Studi Di Milano B Icocca Metodo e kit per la rivelazione di anticorpi.
AU2013287119A1 (en) 2012-07-03 2015-01-22 Janssen Alzheimer Immunotherapy C-terminal and central epitope a-beta antibodies
EP2928494A4 (en) 2012-12-07 2016-11-02 Biogen Internat Neuroscience Gmbh METHOD FOR REDUCING AMYLOIDER PLAQUE OF BRAIN WITH ANTI-ASS ANTIBODIES
US20140314741A1 (en) * 2013-04-18 2014-10-23 Developmen Center For Biotechnology Human Antibody against Interleukin-20 and Treatment for Inflammatory Diseases
US9486559B2 (en) 2013-05-07 2016-11-08 Abbott Cardiovascular Systems Inc. Methods of treatment with a bioresorbable scaffold for neurologic drug delivery
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
US20160355573A1 (en) 2013-09-05 2016-12-08 Cornell University Gene therapy for alzheimer's and other neurodegenerative diseases and conditions
PE20161093A1 (es) * 2013-12-20 2016-10-23 Neurimmune Holding Ag Terapia basada en anticuerpos de amiloidosis por transtiretina (ttr) y anticuerpos derivados de humanos de la misma
TW202239429A (zh) 2014-02-08 2022-10-16 美商建南德克公司 治療阿茲海默症之方法
US10562973B2 (en) 2014-04-08 2020-02-18 Prothena Bioscience Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
WO2015172837A1 (en) 2014-05-16 2015-11-19 Universitat Autonoma De Barcelona SINGLE CHAIN VARIABLE FRAGMENT (scFv) ELONGATION MUTANTS
WO2015191934A2 (en) * 2014-06-11 2015-12-17 Abbvie Inc. Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases
CN106661103B (zh) 2014-07-10 2020-11-03 生命北极神经科学公司 改进的Aβ初原纤维结合抗体
EP3174898A2 (en) 2014-07-29 2017-06-07 Neurimmune Holding AG Human-derived anti-huntingtin (htt) antibodies and uses thereof
WO2016040903A1 (en) 2014-09-11 2016-03-17 Board Of Regents Of The University Of Texas System Detection of misfolded amyloid beta protein
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
US20170363645A1 (en) 2014-12-19 2017-12-21 Probiodrug Ag Novel Method for the Detection of pGlu-Abeta Peptides
US10494425B2 (en) 2015-02-24 2019-12-03 Rpeptide, Llc Anti-amyloid-beta antibodies
NZ739181A (en) 2015-07-16 2023-05-26 Vivoryon Therapeutics N V Anti-pyroglutamated amyloid beta humanized antibodies
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
JOP20170004B1 (ar) 2016-01-15 2022-09-15 Lilly Co Eli الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
EP3405489A1 (en) 2016-01-20 2018-11-28 Genentech, Inc. High dose treatments for alzheimer's disease
PL3430397T3 (pl) 2016-03-14 2022-04-04 Biogen International Neuroscience Gmbh Oznaczenie fagocytozy zależnej od przeciwciał do wiarygodnych pomiarów wychwytu zagregowanych białek
US11596699B2 (en) 2016-04-29 2023-03-07 CureVac SE RNA encoding an antibody
MX2018015022A (es) 2016-06-07 2019-08-14 Biogen Int Neuroscience Gmbh Métodos para el tratamiento de la enfermedad de alzheimer.
EP3487531A4 (en) 2016-07-19 2020-03-25 Annexon, Inc. TREATMENT OF FRONTO-TEMPORAL DEMENTIA
KR102630042B1 (ko) 2016-10-27 2024-01-29 에자이 알앤드디 매니지먼트 가부시키가이샤 알츠하이머병의 치료를 위한 항-a베타 원시섬유 항체 및 베타-세크레타제 bace1 억제제를 포함하는 조성물
TW201827467A (zh) 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白-β之抗體及其用途
RU2019114679A (ru) 2016-11-15 2020-12-17 Х. Лундбекк А/С Средства, пути применения и способы лечения синуклеопатии
WO2018119001A1 (en) 2016-12-19 2018-06-28 Fred Hutchinson Cancer Research Center Peptide-antibody compositions and methods of use thereof
EP3354278A1 (en) 2017-01-31 2018-08-01 Sanofi Neuronal cell protective effect of antibodies specific for the protofibrillar form of the beta-amyloid peptide
WO2018204408A1 (en) 2017-05-02 2018-11-08 Sanford Burnham Prebys Medical Discovery Institute Methods of diagnosing and treating alzheimer's disease
EP3431496A1 (en) 2017-07-19 2019-01-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti- isoasp7 amyloid beta antibodies and uses thereof
MD3672631T3 (ro) 2017-08-22 2023-09-30 Biogen Ma Inc Compoziții farmaceutice conținând anticorpi anti-beta amiloidici
CA3076313A1 (en) 2017-09-28 2019-04-04 Prothena Biosciences Limited Dosing regimes for treatment of synucleinopathies
US20190153102A1 (en) 2017-09-28 2019-05-23 Prothena Biosciences Limited Dosing regimes for treatment of synucleinopathies
US20200330592A1 (en) 2017-10-09 2020-10-22 Keith Black Compositions and methods of treating alzheimer's and other amyloid related diseases
US12344662B2 (en) 2018-02-09 2025-07-01 The Trustees Of Dartmouth College Chimeric antigen receptors for treatment of neurodegenerative diseases and disorders
WO2020015637A1 (zh) 2018-07-17 2020-01-23 江苏恒瑞医药股份有限公司 抗Abeta抗体、其抗原结合片段及应用
WO2020023530A2 (en) 2018-07-24 2020-01-30 Eisai R&D Management Co., Ltd. Methods of treatment and prevention of alzheimer's disease
US12259395B2 (en) 2018-08-17 2025-03-25 Ab Studio Inc. Catabodies and methods of use thereof
MX2021004819A (es) 2018-11-02 2021-06-08 Annexon Inc Composiciones y metodos para tratar lesiones cerebrales.
CA3129890A1 (en) 2019-02-12 2020-08-20 Prothena Biosciences Limited Treatment of al amyloidosis with the combination of monoclonal antibodies against immunoglobulin light chains and the cd38 cell membrane molecule on antibody-producing and other immune cells
SG11202110504XA (en) 2019-03-26 2021-10-28 Janssen Pharmaceutica Nv ANTIBODIES TO PYROGLUTAMATE AMYLOID-ß AND USES THEREOF
EP4010367A4 (en) 2019-04-04 2023-10-11 The Royal Institution for the Advancement of Learning / McGill University Use of ass34 to assess alzheimer's disease progression
WO2020257745A1 (en) 2019-06-21 2020-12-24 University Of Kansas Compositions and methods useful in treating brain diseases
ES2821599A1 (es) 2019-10-24 2021-04-26 Univ Del Pais Vasco / Euskal Herriko Unibertsitatea Compuestos y metodos para el tratamiento de la enfermedad de alzheimer
JP2023506450A (ja) 2019-12-11 2023-02-16 アンベテックス ピーティーワイ エルティーディー 拡張機能障害の防止及び治療のためのアミロイドベータ抗体又はワクチンを含む療法組成物
PT4121007T (pt) 2020-03-20 2025-09-25 Eisai R&D Man Co Ltd Formulações de anticorpo de protofibrila de péptido anti-beta amiloide de concentração alta e métodos de uso das mesmas
AU2021310926A1 (en) 2020-07-23 2023-03-23 Othair Prothena Limited Anti-abeta antibodies

Similar Documents

Publication Publication Date Title
CN114502591B (zh) 靶向bcma的抗体、双特异性抗体及其用途
JP2022169598A (ja) タウ認識抗体
AU2020213579B2 (en) Anti-PD-1 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
US20200347130A1 (en) CD96 Antibody, Antigen-Binding Fragment and Pharmaceutical use Thereof
US12227583B2 (en) Anti-OX40 antibody, antigen-binding fragment thereof, and the pharmaceutical use
RU2012112340A (ru) Гуманизированные моноклональные антитела к сеа с созревшей аффинностью
JP2022506719A (ja) タウ認識抗体
RU2006123481A (ru) Nogo-a-нейтрализующие иммуноглобулины для лечения неврологических заболеваний
CN103347896A (zh) 抗cxcl13抗体和其使用方法
WO2009074583A1 (en) Antigen binding proteins
RU2014131317A (ru) Связывающие mica агенты
CA3077304C (en) Anti-pacap antibody
EP2200699A1 (en) Antigen binding proteins
US20240383980A1 (en) CD3/CD25 Antibodies For Neuro-Immune Diseases
CN102740877B (zh) 对源自hsp65的肽-6有特异性的人源化抗体及其方法和用途
JP2021512652A5 (cg-RX-API-DMAC7.html)
US9493561B2 (en) Antibodies to Toso
US20220380446A1 (en) Antibodies for treating alpha-synucleinopathies
JP2022525332A (ja) 免疫抑制の方法
JP2011024537A (ja) トランスポーターに対する抗体およびその用途
NZ761020B2 (en) Cd38 modulating antibody
HK40045557A (en) An anti-ox40 antibody, antigen-binding fragment thereof, and the pharmaceutical use
NZ761838B2 (en) Cd38 antibody
NZ760342B2 (en) Cd38 modulating antibody
NZ761838A (en) Cd38 antibody